Breast cancer is the most common malignant tumour in women,and it has a high incidence and mortality rate both in the world and in China.Hormone receptor-positive breast cancer accounts for about 60–70%of breast canc...Breast cancer is the most common malignant tumour in women,and it has a high incidence and mortality rate both in the world and in China.Hormone receptor-positive breast cancer accounts for about 60–70%of breast cancer and is the most common subtype of advanced breast cancer.Cyclin-dependent kinase 4 and 6(CDK 4/6)inhibitors in combination with endocrine therapy have emerged as the treatment of choice for hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer.Emergence inhibitors of CDK 4/6 have significantly improved outcomes in patients with hormone receptor-positive advanced breast cancer.It is an indisputable fact that cardiotoxicity caused by breast cancer treatment can have a significant impact on the quality of life of cancer survivors;however,there are few studies on the cardiovascular toxicity of CDK 4/6 inhibitors.This article reviews the cardiovascular toxicity and related mechanisms that may be caused by CDK 4/6 inhibitors.展开更多
In recent years,advances in the treatment of malignant tumors have significantly extended the survival of patients with cancer.As tumors increasingly present as chronic diseases,the cardiovascular toxicity associated ...In recent years,advances in the treatment of malignant tumors have significantly extended the survival of patients with cancer.As tumors increasingly present as chronic diseases,the cardiovascular toxicity associated with cancer treatment has become more prominent,impacting treatment efficacy and patient survival.As a result,cardio-oncology has emerged as a rapidly growing discipline;however,cardiovascular diseases in patients with cancer often have an insidious onset,and early identification and treatment are frequently overlooked.The Chinese expert consensus is based on a systematic review of the rational application of cardiac biomarkers for cardiovascular disease risk stratification,early identification,and patient screening throughout the course of cancer treatment.The consensus provides 26 recommendations,each supported by evidence and explanations,aiming to improve the early diagnosis and treatment of cardiovascular disease in patients with cancer.These guidelines provide a basis for standardized screening and management of cardiovascular toxicity related to cancer treatment through the reasonable application of cardiac biomarkers.This review discusses key points of this consensus.展开更多
To the Editor:De-escalating the treatment of ductal carcinoma in situ(DCIS)of the breast has been investigated in recent years.A 5-year adjuvant endocrine therapy(AET)regimen is the recommended treatment for hormone r...To the Editor:De-escalating the treatment of ductal carcinoma in situ(DCIS)of the breast has been investigated in recent years.A 5-year adjuvant endocrine therapy(AET)regimen is the recommended treatment for hormone receptor-positive DCIS.Selective estrogen receptor modulators(such as the commonly used tamoxifen and toremifene)and aromatase inhibitors(AIs)are the currently used AET drugs.However,long-term AET is accompanied by severe side effects such as menopausal symptoms,endometrial carcinoma,cardiovascular events,venous thromboembolic events,osteoporosis,and joint pain that can significantly reduce patients’quality of life.It was reported that only 50%of the patients completed the recommended 5-year AET mainly because of side effects,while higher adherence rates were observed with shorter-duration regimens.[1,2]Therefore,de-escalation of AET should be considered to reduce the side effects of AET and improve adherence.展开更多
文摘Breast cancer is the most common malignant tumour in women,and it has a high incidence and mortality rate both in the world and in China.Hormone receptor-positive breast cancer accounts for about 60–70%of breast cancer and is the most common subtype of advanced breast cancer.Cyclin-dependent kinase 4 and 6(CDK 4/6)inhibitors in combination with endocrine therapy have emerged as the treatment of choice for hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer.Emergence inhibitors of CDK 4/6 have significantly improved outcomes in patients with hormone receptor-positive advanced breast cancer.It is an indisputable fact that cardiotoxicity caused by breast cancer treatment can have a significant impact on the quality of life of cancer survivors;however,there are few studies on the cardiovascular toxicity of CDK 4/6 inhibitors.This article reviews the cardiovascular toxicity and related mechanisms that may be caused by CDK 4/6 inhibitors.
文摘In recent years,advances in the treatment of malignant tumors have significantly extended the survival of patients with cancer.As tumors increasingly present as chronic diseases,the cardiovascular toxicity associated with cancer treatment has become more prominent,impacting treatment efficacy and patient survival.As a result,cardio-oncology has emerged as a rapidly growing discipline;however,cardiovascular diseases in patients with cancer often have an insidious onset,and early identification and treatment are frequently overlooked.The Chinese expert consensus is based on a systematic review of the rational application of cardiac biomarkers for cardiovascular disease risk stratification,early identification,and patient screening throughout the course of cancer treatment.The consensus provides 26 recommendations,each supported by evidence and explanations,aiming to improve the early diagnosis and treatment of cardiovascular disease in patients with cancer.These guidelines provide a basis for standardized screening and management of cardiovascular toxicity related to cancer treatment through the reasonable application of cardiac biomarkers.This review discusses key points of this consensus.
基金funded by grants from the 2023 Applied Basic research project of Liaoning province(No.2023JH2/101300048 to B.Chen)2021 Science and Technology project of Shenyang(No.21-173-9-07 to G.Zhu).
文摘To the Editor:De-escalating the treatment of ductal carcinoma in situ(DCIS)of the breast has been investigated in recent years.A 5-year adjuvant endocrine therapy(AET)regimen is the recommended treatment for hormone receptor-positive DCIS.Selective estrogen receptor modulators(such as the commonly used tamoxifen and toremifene)and aromatase inhibitors(AIs)are the currently used AET drugs.However,long-term AET is accompanied by severe side effects such as menopausal symptoms,endometrial carcinoma,cardiovascular events,venous thromboembolic events,osteoporosis,and joint pain that can significantly reduce patients’quality of life.It was reported that only 50%of the patients completed the recommended 5-year AET mainly because of side effects,while higher adherence rates were observed with shorter-duration regimens.[1,2]Therefore,de-escalation of AET should be considered to reduce the side effects of AET and improve adherence.
